for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

GlaxoSmithKline plc

GSK.L

Latest Trade

1,684.20GBp

Change

9.20(+0.55%)

Volume

1,804,550

Today's Range

1,675.00

 - 

1,697.00

52 Week Range

1,408.80

 - 

1,770.60

As of on the London Stock Exchange (LON) ∙ Minimum 15 minute delay

Pricing

Previous Close
1,675.00
Open
1,677.40
Volume
1,804,550
3M AVG Volume
142.50
Today's High
1,697.00
Today's Low
1,675.00
52 Week High
1,770.60
52 Week Low
1,408.80
Shares Out (MIL)
4,988.72
Market Cap (MIL)
83,561.13
Forward P/E
14.35
Dividend (Yield %)
--

Next Event

Q3 2019 GlaxoSmithKline PLC Earnings Release

Latest Developments

More

UK's MHRA Issues Drug Alert As GlaxoSmithKline Recalls All Unexpired Zantac Stock

Gsk And Lyell Immunopharma To Develop Next Generation Of Cancer Cell Therapies

Vectura Says UK Court Dismissed GSK's Claims Of Passing Off In Respect Of Sandoz's Airflusal Forspiro

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About GlaxoSmithKline plc

GlaxoSmithKline PLC is a global healthcare company. The Company operates through two segments: Pharmaceuticals and Vaccines. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases. The Company makes a range of prescription medicines and vaccines products. The Pharmaceuticals business discovers, develops and commercializes medicines to treat a range of acute and chronic diseases. The Vaccines business provides vaccines for people of all ages from babies and adolescents to adults and older people. It has a portfolio of medicines in respiratory and HIV. Its Pharmaceuticals business includes Respiratory, HIV, Specialty products, and Classic and Established products. Its Vaccines business has a portfolio of over 40 pediatric, adolescent, adult, older people and travel vaccines.

Industry

Biotechnology & Drugs

Contact Info

G S K House, 980 Great West Road

+44.20.80475000

https://www.gsk.com/

Executive Leadership

Jonathan Richard Symonds

Independent Non-Executive Chairman of the Board

Emma N. Walmsley

Chief Executive Officer, Executive Director

Iain James Mackay

Chief Financial Officer, Executive Director

Roger G. Connor

President - Vaccines

Brian McNamara

Chief Executive Officer - GSK Consumer Healthcare

Key Stats

2.62 mean rating - 26 analysts
Sell
Hold
Buy
Revenue (MM, GBP)

2016

27.9K

2017

30.2K

2018

30.8K

2019(E)

32.6K
EPS (GBp)

2016

102.400

2017

111.800

2018

119.400

2019(E)

116.700
Price To Earnings (TTM)
18.33
Price To Sales (TTM)
2.63
Price To Book (MRQ)
23.12
Price To Cash Flow (TTM)
10.30
Total Debt To Equity (MRQ)
925.84
LT Debt To Equity (MRQ)
645.07
Return on Investment (TTM)
12.65
Return on Equity (TTM)
8.20

Latest News

Latest News

GSK recalls popular heartburn drug Zantac globally after cancer scare

GlaxoSmithKline <GSK.L> on Tuesday said it is recalling the popular heartburn medicine Zantac in all markets as a "precaution", days after the U.S. Food and Drug Administration found "unacceptable" levels of probable cancer-causing impurity in the drug.

GSK recalls popular heartburn medicine Zantac - U.K. medicines watchdog

GlaxoSmithKline Plc is recalling its heartburn medicine Zantac as a "precautionary measure" due to a probable cancer-causing impurity in the drug, Britain's medicines watchdog said on Tuesday.

Vectura, Sandoz win ruling on inhaler packaging case against GSK

Vectura Group said on Friday a British court had ruled in its favor on the packaging of a generic version of an inhaler made by bigger rival GlaxoSmithKline.

GlaxoSmithKline's cancer therapy cuts risk of disease progression or death by 38%

GlaxoSmithKline plc said on Monday its maintenance therapy for a form of ovarian cancer reduced the risk of disease progression or death by 38% in a late-stage study in cancer patients.

Results of GSK and AstraZeneca trials may widen ovarian cancer drug use

GlaxoSmithKline and AstraZeneca both reported trial results that will likely make their competing drugs available to a wider group of ovarian cancer patients, possibly helping GSK catch its rival in a highly contested drug class.

Separate GSK, AstraZeneca trial results may widen ovarian cancer drug use

GlaxoSmithKline and AstraZeneca both reported trial results that will likely make their competing drugs available to a wider group of ovarian cancer patients, possibly helping GSK catch its rival in a highly contested drug class.

GSK, AstraZeneca rivalry takes center stage at cancer conference

GlaxoSmithKline and AstraZeneca will each present trial data on a promising new class of drugs against ovarian cancer on Saturday as Britain's top drugmakers compete to burnish their oncology credentials.

Microsoft nominates GSK CEO Walmsley to board

Microsoft Corp <MSFT.O> said on Thursday it has nominated GlaxoSmithKline Plc <GSK.L> Chief Executive Officer Emma Walmsley to its board of directors.

GSK's over-the-counter nicotine oral spray gets FDA panel backing

An independent expert panel to the U.S. Food and Drug Administration on Wednesday recommended approval of GlaxoSmithKline Plc's <GSK.L> over-the-counter nicotine oral spray that aims to help smokers quit their addiction.

FDA panel recommends GSK's over-the-counter nicotine oral spray

An independent expert panel to the U.S. Food and Drug Administration on Wednesday recommended approval of GlaxoSmithKline Plc's over-the-counter nicotine oral spray that aims to help smokers quit their nicotine addiction.

UPDATE 2-AstraZeneca respiratory business gets boost from 3-drug inhaler results

* Fasenra gets U.S. FDA orphan drug status (Adds details on Breztri data)

GSK builds oncology pipeline as drug shown to help myeloma patients

GlaxoSmithKline said an experimental multiple myeloma treatment has shown a meaningful response in patients that have run out of three previous treatment options, in a boost for the British drugmaker's cancer drug business.

GSK's long acting HIV injection gets boost from study

GlaxoSmithKline's experimental HIV injection is as effective when given every other month as monthly, according to a study, a convenience that could help the British drugmaker in its battle against a rival drug from Gilead Sciences.GSK's two-drug injection was as effective...

GSK new HIV two-drug injection meets main goal in late-stage study

British drugmaker GlaxoSmithKline Plc said on Thursday its long-lasting two-drug regimen to treat HIV met the main goal of a late-stage study.

AstraZeneca scores win in race to treat ovarian cancer

AstraZeneca has made further headway in the race with larger competitor GlaxoSmithKline's to use a promising new class of drugs to treat ovarian cancer.

GSK ends development of Ebola vaccine, hands work to U.S. institute

British drugmaker GlaxoSmithKline is giving up its work on developing three potential vaccines against the deadly Ebola and Marburg viruses, despite an ongoing Ebola outbreak in Democratic Republic of Congo.

GSK hands work on potential Ebola vaccines to U.S. institute

British drugmaker GlaxoSmithKline is handing over all its development work on three potential vaccines against the deadly Ebola and Marburg viruses despite an ongoing Ebola outbreak in Democratic Republic of Congo.

GSK raises 2019 earnings expectations after standout quarter for Shingrix

GlaxoSmithKline beat second quarter profit expectations with the help of strong demand for its shingles vaccine, prompting the British drugmaker to forecast a smaller fall in profit this year than originally anticipated.

REFILE-UPDATE 1-GSK predicts smaller fall in 2019 profit after standout quarter for Shingrix

GlaxoSmithKline Plc on Wednesday forecast a smaller than previously estimated fall in full-year profit after the British drugmaker beat profit consensus for the second quarter due to demand for its fast-growing Shingles vaccine.

GSK forecasts smaller hit to FY profit after Q2 beat

GlaxoSmithKline Plc on Wednesday forecast a smaller-than estimated fall in full-year profit after the British drugmaker beat profit consensus for the second quarter due to demand for its fast-growing Shingles vaccine.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up